본문 바로가기

Development of mucoadhesive Timolol loaded chitosan-nanocomposite to treat glaucoma

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 13Scopus 15
FWCI (Scopus)
0.96
JCR IF
JCR 2022 8.2
ISSN
0141-8130

저자

  1. Kumara, B. N.제1저자Yenepoya Deemed Univ, Yenepoya Res Ctr, Nano Div, Nanomat Res Lab NMRL, Mangalore 575018, India
  2. Shambhu, R.Yenepoya Deemed Univ, Yenepoya Med Coll, Dept Ophthalmol, Mangalore 575018, India
  3. 심윤보Pusan Natl Univ, Inst BioPhysio Sensor Technol IBST, Dept Chem, Busan 46241, South Korea
  4. Nirmal, JayabalanBirla Inst Technol & Sci BITS, Dept Pharm, Translat Pharmaceut Res Lab TPRL, Hyderabad Campus, Hyderabad 500078, Telangana, India
  5. Prasad, K. Sudhakara교신저자Yenepoya Deemed Univ, Yenepoya Res Ctr, Nano Div, Nanomat Res Lab NMRL, Mangalore 575018, India

초록

Timolol Maleate is an aqueous soluble β-blocker antiglaucoma drug used to suppress intraocular pressure. Several commercially available ocular formulations are not effective in delivering to the target site due to their water-soluble property and low mucoadhesiveness. Hence, there is a requirement for a highly mucoadhesive drug-loaded nanocomposite to suppress intraocular pressure with enhanced bioavailability. Herein, we have prepared a mucoadhesive Timolol-loaded graphene quantum dot-chitosan-nanocomposite to treat glaucoma in response to lysozyme, secreted in the tear fluid. The as-prepared nanocomposite has been characterized through high resolution-transmission electron microscopic, X-ray photoelectron spectroscopic, X-ray diffraction, and Fourier transform infrared spectral studies. The nanocomposite showed 93.74 % encapsulation efficiency with a loading capacity of 7.73 %. Further, 89.26 %, 95.62 %, and 99.29 % of drug release were observed from the nanocomposite in the presence of 1, 1.5, and 2 mg/mL of lysozyme. The mucoadhesion property has been confirmed by the increment in the particle size, fluorescence spectral variations, and Fourier transform infrared spectroscopic studies in the presence of mucin nanoparticles of size 291 nm. Interestingly, mucoadhesion has been demonstrated by pointing to the quenching in the luminescence of mucin. Further, in vitro biocompatibility assay on human corneal epithelial cells showed ≥80 % cell viability. Hence, this study offers the utilization of naturally secreting enzymes for drug delivery applications instead of uncontrolled pH and temperature-triggered releases.

키워드

ChitosanDrug deliveryGlaucomaLysozymeMucoadhesiveTimololDRUG-DELIVERYNANOPARTICLESMALEATEMUCUS

식별자

Scopus EID
2-s2.0-85171786596
WoS UID
001078716300001